Recent real-world evidence studies that found Medicare patients fared worse on cancer drugs than patients in the clinical trials used for US Food and Drug Administration approval may help push the agency to require more study enrollment of the elderly.
FDA recently indicated it plans to begin a formal effort to encourage and inform drug development in older adults, with Center for Drug Evaluation and Research Deputy Director for Clinical Science Bob Temple saying that it may be possible to require enrollment of particular study populations through regulation
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?